Provincial Cancer Standards & Clinical Practice Guidelines

Provincial Cancer Standards & Clinical Practice Guidelines

This site will provide you with access to current versions of approved provincial cancer standards and Clinical Practice Guidelines as well as additional details regarding these governance documents.

Current Provincial Cancer Standards

Current Clinical Practice Guidelines

Acute Leukemia and Bone Marrow Transplant Practice Guidelines

 

Breast Practice Guidelines

Central Nervous System Practice Guidelines

 

Cutaneous Practice Guidelines

Melanoma

Disease & Symptom Management

 

Endocrine Practice Guidelines

 

Gastro-Intestinal Practice Guidelines

Rectal

Disease & Symptom Management

Gastric Cancer

Disease Management

Genitourinary Practice Guidelines

 

Gynecologic Oncology Practice Guidelines

 

Head and Neck Practice Guidelines

Hematology Practice Guidelines

Hepatocellular Practice Guidelines

Lymphoproliferative Disorders Practice Guidelines

Sarcoma Practice Guidelines

 

Practice Guidelines for Smoking Cessation

Despite a diagnosis of cancer, some patients continue to smoke. Healthcare providers can use this document as a guide to facilitate an evidence-based, shared approach to the clinical support of smoking cessation within oncology care.

For this purpose, it may be used by qualified and licensed healthcare practitioners involved with the care of oncology patients, which may include (but is not limited to): physicians, surgeons, nurses, radiation therapists, pharmacists, psychosocial oncology caregivers and dietitians.

To view this practice guideline, click Supportive Care Smoking Cessation in Oncology Care.

Practice Guidelines for Filgrastim Use in Adults by Disease Site

Neutropenia and its complications such as febrile neutropenia and infection are major toxicities associated with myelosuppressive chemotherapy.

Adverse consequences of febrile neutropenia include hospitalization, use of antibiotics and delays in chemotherapy administration

This document is intended as a guide to facilitate an evidence-informed, shared approach to the appropriate use of filgrastim in adults.

For this purpose, it may be used by qualified and licensed healthcare practitioners involved with the care of oncology patients, which may include (but is not limited to): physicians, surgeons, nurses, radiation therapists, pharmacists, psychosocial oncology caregivers and dietitians

The recommendations are stratified by each Disease Site Group in order to help clarify the indications in which filgrastim should be used.

To view these practice guidelines, click Recommendations for Filgrastim Use in Adults by Disease Site.

Febrile Neutropenia

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer

Disconnecting your Elastomeric Infusor from your PORT or PICC

Thoracic (Lung) Practice Guidelines

Esophageal

Carcinoma of Unknown Primary Practice Guidelines

 

Contacts

For questions related to provincial cancer standards:

E-mail: CCMBCancerStandards@cancercare.mb.ca

Phone: 204-390-7388

For questions related to clinical practice guidelines:

CCMBCPGI@cancercare.mb.ca

Phone: 204-787-8602

Provincial Cancer Standards

Supporting the delivery of consistent, high-quality care for the people of Manitoba

Prevention – Diagnosis – Treatment

CancerCare Manitoba’s (CCMB’s) Office of Cancer Standards was established in October 2023 in response to the Provincial Government’s Health System Governance and Accountability Act.

The Act established CCMB as the provincial cancer authority and outlined our legislated duty to establish, update, monitor and evaluate compliance with clinical standards as they relate to the prevention, diagnosis and treatment of cancer.

What are Standards?

Standards are a set of foundational resources and requirements that must be met to deliver consistent, high-quality care.  Standards establish a minimum benchmark that can be measured.

Standards include:

  • The people involved in delivering the care (e.g. competency and training requirements)
  • The facility where the care is being delivered (e.g. equipment, technology, availability of ancillary and support services)
  • Outcome measures, benchmarks and quality assurance (e.g. wait times, volumes)

How are Standards Developed?

Why do we Need Provincial Cancer Standards?

The goal of standards is to:

  • Improve cancer outcomes
  • Reduce variability among facilities and providers
  • Establish minimum acceptable parameters
  • Foster a culture of continuous quality improvement
  • Promote system sustainability

Ensuring high-quality cancer care services for the people of Manitoba.

Who are Standards For?

Standards are ultimately created to benefit patients.

The primary audience for standards are:

  • Healthcare providers
  • Administrators
  • Program planners
  • Health authorities
  • Policy makers

Adherence to Standards

Measuring alignment with cancer standards is crucial for improving cancer outcomes and promoting continuous quality improvement.  It helps us:

  • understand current quality levels,
  • make informed decisions on quality improvement investments, and
  • assess the effectiveness of quality improvement initiatives over time.

What if Standards are Not Met?

The goal = Supportive vs. Punitive

CCMB collaborates with providers and facilities to identify and address the root causes, implementing quality improvement tools and processes as needed.

Clinical Practice Guidelines

What are Clinical Practice Guidelines?

Clinical Practice Guidelines (CPGs) are systematically developed statements designed to standardize the management of common scenarios and assist healthcare professionals and patients in making decisions about appropriate care for specific clinical circumstances.

CPGs can be applied in various healthcare settings by clinicians in collaboration with patients so the best course of action can be determined when decisions about care delivery or treatment options are being made.

Purpose

CCMB CPGs are designed to outline current standards of care and are to be used as a knowledge translation tool that summarizes current best evidence. The ultimate aim of utilizing practice guidelines is to improve the quality of care.

Methodology

CCMB uses a scoping review methodology which is a type of knowledge synthesis that uses a systemic approach to identify and synthesize filtered information on a specific topic. Scoping reviews at CCMB are conducted by a panel of multidisciplinary experts who review filtered information.

CCMB welcomes the input of healthcare professionals. If you are interested in further learning or participating in the development or review of guidelines, or have questions about the guideline development process please contact: CCMBCPGI@cancercare.mb.ca

How are Clinical Practice Guidelines Developed?

Legal Disclosure for Clinical Practice Guidelines

CCMB CPGs represent the consensus of CCMB professionals regarding their views of currently accepted approaches to treatment. These materials have been published so that qualified and licensed healthcare practitioners can consider this information in determining appropriate care or treatment for their patients. The publication of these materials by CCMB and the consequent knowledge of them by practitioners must not preclude use of practitioner’s independent clinical judgement, nor must such publication and consequent knowledge replace the need for a practitioner to consult with the appropriate care provider if warranted in a particular patient’s circumstances.

It is recommended that practitioners frequently consult this website to ensure that they are aware of the most recent CPGs published by CCMB.